Report Cover

Global and Japan Oncology Biosimilars Market Insights, Forecast to 2026


Oncology Biosimilars market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Oncology Biosimilars market is segmented into
    mAb
    Immunomodulators
    Hematopoietic Agents
    G-CSF
    Others

Segment by Application, the Oncology Biosimilars market is segmented into
    Retail Pharmacies
    Hospital Pharmacy
    Online Pharmacy

Regional and Country-level Analysis
The Oncology Biosimilars market is analysed and market size information is provided by regions (countries).
The key regions covered in the Oncology Biosimilars market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Oncology Biosimilars Market Share Analysis
Oncology Biosimilars market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Oncology Biosimilars business, the date to enter into the Oncology Biosimilars market, Oncology Biosimilars product introduction, recent developments, etc.
The major vendors covered:
    Celltrion
    Biocon
    Dr. Reddy's Laboratories
    STADA Arzneimittel AG
    Intas Pharmaceuticals
    Pfizer
    Sandoz International
    Teva Pharmaceutical Industries Ltd
    Apotex
    BIOCAD
1 Study Coverage
    1.1 Oncology Biosimilars Product Introduction
    1.2 Market Segments
    1.3 Key Oncology Biosimilars Manufacturers Covered: Ranking by Revenue
    1.4 Market by Type
        1.4.1 Global Oncology Biosimilars Market Size Growth Rate by Type
        1.4.2 mAb
        1.4.3 Immunomodulators
        1.4.4 Hematopoietic Agents
        1.4.5 G-CSF
        1.4.6 Others
    1.5 Market by Application
        1.5.1 Global Oncology Biosimilars Market Size Growth Rate by Application
        1.5.2 Retail Pharmacies
        1.5.3 Hospital Pharmacy
        1.5.4 Online Pharmacy
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Oncology Biosimilars Market Size, Estimates and Forecasts
        2.1.1 Global Oncology Biosimilars Revenue 2015-2026
        2.1.2 Global Oncology Biosimilars Sales 2015-2026
    2.2 Global Oncology Biosimilars, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    2.3 Oncology Biosimilars Historical Market Size by Region (2015-2020)
        2.3.1 Global Oncology Biosimilars Retrospective Market Scenario in Sales by Region: 2015-2020
        2.3.2 Global Oncology Biosimilars Retrospective Market Scenario in Revenue by Region: 2015-2020
    2.4 Oncology Biosimilars Market Estimates and Projections by Region (2021-2026)
        2.4.1 Global Oncology Biosimilars Sales Forecast by Region (2021-2026)
        2.4.2 Global Oncology Biosimilars Revenue Forecast by Region (2021-2026)

3 Global Oncology Biosimilars Competitor Landscape by Players
    3.1 Global Top Oncology Biosimilars Sales by Manufacturers
        3.1.1 Global Oncology Biosimilars Sales by Manufacturers (2015-2020)
        3.1.2 Global Oncology Biosimilars Sales Market Share by Manufacturers (2015-2020)
    3.2 Global Oncology Biosimilars Manufacturers by Revenue
        3.2.1 Global Oncology Biosimilars Revenue by Manufacturers (2015-2020)
        3.2.2 Global Oncology Biosimilars Revenue Share by Manufacturers (2015-2020)
        3.2.3 Global Oncology Biosimilars Market Concentration Ratio (CR5 and HHI) (2015-2020)
        3.2.4 Global Top 10 and Top 5 Companies by Oncology Biosimilars Revenue in 2019
        3.2.5 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Global Oncology Biosimilars Price by Manufacturers
    3.4 Global Oncology Biosimilars Manufacturing Base Distribution, Product Types
        3.4.1 Oncology Biosimilars Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Oncology Biosimilars Product Type
        3.4.3 Date of International Manufacturers Enter into Oncology Biosimilars Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
    4.1 Global Oncology Biosimilars Market Size by Type (2015-2020)
        4.1.1 Global Oncology Biosimilars Sales by Type (2015-2020)
        4.1.2 Global Oncology Biosimilars Revenue by Type (2015-2020)
        4.1.3 Oncology Biosimilars Average Selling Price (ASP) by Type (2015-2026)
    4.2 Global Oncology Biosimilars Market Size Forecast by Type (2021-2026)
        4.2.1 Global Oncology Biosimilars Sales Forecast by Type (2021-2026)
        4.2.2 Global Oncology Biosimilars Revenue Forecast by Type (2021-2026)
        4.2.3 Oncology Biosimilars Average Selling Price (ASP) Forecast by Type (2021-2026)
    4.3 Global Oncology Biosimilars Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
    5.1 Global Oncology Biosimilars Market Size by Application (2015-2020)
        5.1.1 Global Oncology Biosimilars Sales by Application (2015-2020)
        5.1.2 Global Oncology Biosimilars Revenue by Application (2015-2020)
        5.1.3 Oncology Biosimilars Price by Application (2015-2020)
    5.2 Oncology Biosimilars Market Size Forecast by Application (2021-2026)
        5.2.1 Global Oncology Biosimilars Sales Forecast by Application (2021-2026)
        5.2.2 Global Oncology Biosimilars Revenue Forecast by Application (2021-2026)
        5.2.3 Global Oncology Biosimilars Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application
    6.1 Japan Oncology Biosimilars Market Size YoY Growth 2015-2026
        6.1.1 Japan Oncology Biosimilars Sales YoY Growth 2015-2026
        6.1.2 Japan Oncology Biosimilars Revenue YoY Growth 2015-2026
        6.1.3 Japan Oncology Biosimilars Market Share in Global Market 2015-2026
    6.2 Japan Oncology Biosimilars Market Size by Players (International and Local Players)
        6.2.1 Japan Top Oncology Biosimilars Players by Sales (2015-2020)
        6.2.2 Japan Top Oncology Biosimilars Players by Revenue (2015-2020)
    6.3 Japan Oncology Biosimilars Historic Market Review by Type (2015-2020)
        6.3.1 Japan Oncology Biosimilars Sales Market Share by Type (2015-2020)
        6.3.2 Japan Oncology Biosimilars Revenue Market Share by Type (2015-2020)
        6.3.3 Japan Oncology Biosimilars Price by Type (2015-2020)
    6.4 Japan Oncology Biosimilars Market Estimates and Forecasts by Type (2021-2026)
        6.4.1 Japan Oncology Biosimilars Sales Forecast by Type (2021-2026)
        6.4.2 Japan Oncology Biosimilars Revenue Forecast by Type (2021-2026)
        6.4.3 Japan Oncology Biosimilars Price Forecast by Type (2021-2026)
    6.5 Japan Oncology Biosimilars Historic Market Review by Application (2015-2020)
        6.5.1 Japan Oncology Biosimilars Sales Market Share by Application (2015-2020)
        6.5.2 Japan Oncology Biosimilars Revenue Market Share by Application (2015-2020)
        6.5.3 Japan Oncology Biosimilars Price by Application (2015-2020)
    6.6 Japan Oncology Biosimilars Market Estimates and Forecasts by Application (2021-2026)
        6.6.1 Japan Oncology Biosimilars Sales Forecast by Application (2021-2026)
        6.6.2 Japan Oncology Biosimilars Revenue Forecast by Application (2021-2026)
        6.6.3 Japan Oncology Biosimilars Price Forecast by Application (2021-2026)

7 North America
    7.1 North America Oncology Biosimilars Market Size YoY Growth 2015-2026
    7.2 North America Oncology Biosimilars Market Facts & Figures by Country
        7.2.1 North America Oncology Biosimilars Sales by Country (2015-2020)
        7.2.2 North America Oncology Biosimilars Revenue by Country (2015-2020)
        7.2.3 U.S.
        7.2.4 Canada

8 Europe
    8.1 Europe Oncology Biosimilars Market Size YoY Growth 2015-2026
    8.2 Europe Oncology Biosimilars Market Facts & Figures by Country
        8.2.1 Europe Oncology Biosimilars Sales by Country
        8.2.2 Europe Oncology Biosimilars Revenue by Country
        8.2.3 Germany
        8.2.4 France
        8.2.5 U.K.
        8.2.6 Italy
        8.2.7 Russia

9 Asia Pacific
    9.1 Asia Pacific Oncology Biosimilars Market Size YoY Growth 2015-2026
    9.2 Asia Pacific Oncology Biosimilars Market Facts & Figures by Country
        9.2.1 Asia Pacific Oncology Biosimilars Sales by Region (2015-2020)
        9.2.2 Asia Pacific Oncology Biosimilars Revenue by Region
        9.2.3 China
        9.2.4 Japan
        9.2.5 South Korea
        9.2.6 India
        9.2.7 Australia
        9.2.8 Taiwan
        9.2.9 Indonesia
        9.2.10 Thailand
        9.2.11 Malaysia
        9.2.12 Philippines
        9.2.13 Vietnam

10 Latin America
    10.1 Latin America Oncology Biosimilars Market Size YoY Growth 2015-2026
    10.2 Latin America Oncology Biosimilars Market Facts & Figures by Country
        10.2.1 Latin America Oncology Biosimilars Sales by Country
        10.2.2 Latin America Oncology Biosimilars Revenue by Country
        10.2.3 Mexico
        10.2.4 Brazil
        10.2.5 Argentina

11 Middle East and Africa
    11.1 Middle East and Africa Oncology Biosimilars Market Size YoY Growth 2015-2026
    11.2 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country
        11.2.1 Middle East and Africa Oncology Biosimilars Sales by Country
        11.2.2 Middle East and Africa Oncology Biosimilars Revenue by Country
        11.2.3 Turkey
        11.2.4 Saudi Arabia
        11.2.5 U.A.E

12 Company Profiles
    12.1 Celltrion
        12.1.1 Celltrion Corporation Information
        12.1.2 Celltrion Description and Business Overview
        12.1.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
        12.1.4 Celltrion Oncology Biosimilars Products Offered
        12.1.5 Celltrion Recent Development
    12.2 Biocon
        12.2.1 Biocon Corporation Information
        12.2.2 Biocon Description and Business Overview
        12.2.3 Biocon Sales, Revenue and Gross Margin (2015-2020)
        12.2.4 Biocon Oncology Biosimilars Products Offered
        12.2.5 Biocon Recent Development
    12.3 Dr. Reddy's Laboratories
        12.3.1 Dr. Reddy's Laboratories Corporation Information
        12.3.2 Dr. Reddy's Laboratories Description and Business Overview
        12.3.3 Dr. Reddy's Laboratories Sales, Revenue and Gross Margin (2015-2020)
        12.3.4 Dr. Reddy's Laboratories Oncology Biosimilars Products Offered
        12.3.5 Dr. Reddy's Laboratories Recent Development
    12.4 STADA Arzneimittel AG
        12.4.1 STADA Arzneimittel AG Corporation Information
        12.4.2 STADA Arzneimittel AG Description and Business Overview
        12.4.3 STADA Arzneimittel AG Sales, Revenue and Gross Margin (2015-2020)
        12.4.4 STADA Arzneimittel AG Oncology Biosimilars Products Offered
        12.4.5 STADA Arzneimittel AG Recent Development
    12.5 Intas Pharmaceuticals
        12.5.1 Intas Pharmaceuticals Corporation Information
        12.5.2 Intas Pharmaceuticals Description and Business Overview
        12.5.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
        12.5.4 Intas Pharmaceuticals Oncology Biosimilars Products Offered
        12.5.5 Intas Pharmaceuticals Recent Development
    12.6 Pfizer
        12.6.1 Pfizer Corporation Information
        12.6.2 Pfizer Description and Business Overview
        12.6.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
        12.6.4 Pfizer Oncology Biosimilars Products Offered
        12.6.5 Pfizer Recent Development
    12.7 Sandoz International
        12.7.1 Sandoz International Corporation Information
        12.7.2 Sandoz International Description and Business Overview
        12.7.3 Sandoz International Sales, Revenue and Gross Margin (2015-2020)
        12.7.4 Sandoz International Oncology Biosimilars Products Offered
        12.7.5 Sandoz International Recent Development
    12.8 Teva Pharmaceutical Industries Ltd
        12.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
        12.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
        12.8.3 Teva Pharmaceutical Industries Ltd Sales, Revenue and Gross Margin (2015-2020)
        12.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Products Offered
        12.8.5 Teva Pharmaceutical Industries Ltd Recent Development
    12.9 Apotex
        12.9.1 Apotex Corporation Information
        12.9.2 Apotex Description and Business Overview
        12.9.3 Apotex Sales, Revenue and Gross Margin (2015-2020)
        12.9.4 Apotex Oncology Biosimilars Products Offered
        12.9.5 Apotex Recent Development
    12.10 BIOCAD
        12.10.1 BIOCAD Corporation Information
        12.10.2 BIOCAD Description and Business Overview
        12.10.3 BIOCAD Sales, Revenue and Gross Margin (2015-2020)
        12.10.4 BIOCAD Oncology Biosimilars Products Offered
        12.10.5 BIOCAD Recent Development
    12.11 Celltrion
        12.11.1 Celltrion Corporation Information
        12.11.2 Celltrion Description and Business Overview
        12.11.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
        12.11.4 Celltrion Oncology Biosimilars Products Offered
        12.11.5 Celltrion Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Porter's Five Forces Analysis
    13.5 Primary Interviews with Key Oncology Biosimilars Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Oncology Biosimilars Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer

List of Tables Table 1. Oncology Biosimilars Market Segments Table 2. Ranking of Global Top Oncology Biosimilars Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Oncology Biosimilars Market Size Growth Rate by Type 2020-2026 (K g) & (US$ Million) Table 4. Major Manufacturers of mAb Table 5. Major Manufacturers of Immunomodulators Table 6. Major Manufacturers of Hematopoietic Agents Table 7. Major Manufacturers of G-CSF Table 8. Major Manufacturers of Others Table 9. Global Oncology Biosimilars Market Size Growth Rate by Application 2020-2026 (K g) Table 10. Global Oncology Biosimilars Market Size by Region (K g) & (US$ Million): 2020 VS 2026 Table 11. Global Oncology Biosimilars Sales by Regions 2015-2020 (K g) Table 12. Global Oncology Biosimilars Sales Market Share by Regions (2015-2020) Table 13. Global Oncology Biosimilars Revenue by Regions 2015-2020 (US$ Million) Table 14. Global Oncology Biosimilars Sales Forecast by Region (2021-2026) (K g) Table 15. Global Oncology Biosimilars Sales by Manufacturers (2015-2020) (K g) Table 16. Global Oncology Biosimilars Sales Share by Manufacturers (2015-2020) Table 17. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 18. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Biosimilars as of 2019) Table 19. Oncology Biosimilars Revenue by Manufacturers (2015-2020) (US$ Million) Table 20. Oncology Biosimilars Revenue Share by Manufacturers (2015-2020) Table 21. Key Manufacturers Oncology Biosimilars Price (2015-2020) (USD/Unit) Table 22. Oncology Biosimilars Manufacturers Manufacturing Base Distribution and Headquarters Table 23. Manufacturers Oncology Biosimilars Product Type Table 24. Date of International Manufacturers Enter into Oncology Biosimilars Market Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans Table 26. Global Oncology Biosimilars Sales by Type (2015-2020) (K g) Table 27. Global Oncology Biosimilars Sales Share by Type (2015-2020) Table 28. Global Oncology Biosimilars Revenue by Type (2015-2020) (US$ Million) Table 29. Global Oncology Biosimilars Revenue Share by Type (2015-2020) Table 30. Oncology Biosimilars Average Selling Price (ASP) by Type 2015-2020 (USD/Unit) Table 31. Global Oncology Biosimilars Sales Share by Type (2021-2026) Table 32. Global Oncology Biosimilars Sales by Application (2015-2020) (K g) Table 33. Global Oncology Biosimilars Sales Share by Application (2015-2020) Table 34. Global Oncology Biosimilars Sales Share by Application (2021-2026) Table 35. Global Oncology Biosimilars Sales Market Share Forecast by Application (2021-2026) Table 36. Global Oncology Biosimilars Revenue by Application (2015-2020) (US$ Million) Table 37. Global Oncology Biosimilars Revenue Market Share Forecast by Application (2021-2026) Table 38. Japan Oncology Biosimilars Sales (K g) of Key Companies (2015-2020) Table 39. Japan Oncology Biosimilars Sales Share by Company (2015-2020) Table 40. Japan Oncology Biosimilars Revenue (US$ Million) by Company (2015-2020) Table 41. Japan Oncology Biosimilars Sales (K g) by Type (2015-2020) Table 42. Japan Oncology Biosimilars Sales Share by Type (2015-2020) Table 43. Japan Oncology Biosimilars Revenue (US$ Million) Market Share by Type (2015-2020) Table 44. Japan Oncology Biosimilars Price (K g) by Type (2015-2020) Table 45. Japan Oncology Biosimilars Sales (K g) by Type (2021-2026) Table 46. Japan Oncology Biosimilars Sales Share by Type (2021-2026) Table 47. Japan Oncology Biosimilars Revenue (US$ Million) Market Share by Type (2021-2026) Table 48. Japan Oncology Biosimilars Revenue Share by Type (2021-2026) Table 49. Japan Oncology Biosimilars Price (K g) by Type (2021-2026) Table 50. Japan Oncology Biosimilars Sales (K g) by Application (2015-2020) Table 51. Japan Oncology Biosimilars Sales Share by Application (2015-2020) Table 52. Japan Oncology Biosimilars Revenue (US$ Million) Market Share by Application (2015-2020) Table 53. Japan Oncology Biosimilars Sales (K g) by Application (2021-2026) Table 54. Japan Oncology Biosimilars Sales Share by Application (2021-2026) Table 55. Japan Oncology Biosimilars Revenue (US$ Million) Market Share by Application (2021-2026) Table 56. Japan Oncology Biosimilars Revenue Share by Application (2021-2026) Table 57. North America Oncology Biosimilars Sales by Country (2015-2020) (K g) Table 58. North America Oncology Biosimilars Sales Market Share by Country (2015-2020) Table 59. North America Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million) Table 60. North America Oncology Biosimilars Revenue Market Share by Country (2015-2020) Table 61. Europe Oncology Biosimilars Sales by Country (2015-2020) (K g) Table 62. Europe Oncology Biosimilars Sales Market Share by Country (2015-2020) Table 63. Europe Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million) Table 64. Europe Oncology Biosimilars Revenue Market Share by Country (2015-2020) Table 65. Asia Pacific Oncology Biosimilars Sales by Region (2015-2020) (K g) Table 66. Asia Pacific Oncology Biosimilars Sales Market Share by Region (2015-2020) Table 67. Asia Pacific Oncology Biosimilars Revenue by Region (2015-2020) (US$ Million) Table 68. Asia Pacific Oncology Biosimilars Revenue Market Share by Region (2015-2020) Table 69. Latin America Oncology Biosimilars Sales by Country (2015-2020) (K g) Table 70. Latin America Oncology Biosimilars Sales Market Share by Country (2015-2020) Table 71. Latin Americaa Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million) Table 72. Latin America Oncology Biosimilars Revenue Market Share by Country (2015-2020) Table 73. Middle East and Africa Oncology Biosimilars Sales by Country (2015-2020) (K g) Table 74. Middle East and Africa Oncology Biosimilars Sales Market Share by Country (2015-2020) Table 75. Middle East and Africa Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million) Table 76. Middle East and Africa Oncology Biosimilars Revenue Market Share by Country (2015-2020) Table 77. Celltrion Corporation Information Table 78. Celltrion Description and Business Overview Table 79. Celltrion Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 80. Celltrion Oncology Biosimilars Product Table 81. Celltrion Recent Development Table 82. Biocon Corporation Information Table 83. Biocon Description and Business Overview Table 84. Biocon Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 85. Biocon Product Table 86. Biocon Recent Development Table 87. Dr. Reddy's Laboratories Corporation Information Table 88. Dr. Reddy's Laboratories Description and Business Overview Table 89. Dr. Reddy's Laboratories Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 90. Dr. Reddy's Laboratories Product Table 91. Dr. Reddy's Laboratories Recent Development Table 92. STADA Arzneimittel AG Corporation Information Table 93. STADA Arzneimittel AG Description and Business Overview Table 94. STADA Arzneimittel AG Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 95. STADA Arzneimittel AG Product Table 96. STADA Arzneimittel AG Recent Development Table 97. Intas Pharmaceuticals Corporation Information Table 98. Intas Pharmaceuticals Description and Business Overview Table 99. Intas Pharmaceuticals Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 100. Intas Pharmaceuticals Product Table 101. Intas Pharmaceuticals Recent Development Table 102. Pfizer Corporation Information Table 103. Pfizer Description and Business Overview Table 104. Pfizer Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 105. Pfizer Product Table 106. Pfizer Recent Development Table 107. Sandoz International Corporation Information Table 108. Sandoz International Description and Business Overview Table 109. Sandoz International Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 110. Sandoz International Product Table 111. Sandoz International Recent Development Table 112. Teva Pharmaceutical Industries Ltd Corporation Information Table 113. Teva Pharmaceutical Industries Ltd Description and Business Overview Table 114. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 115. Teva Pharmaceutical Industries Ltd Product Table 116. Teva Pharmaceutical Industries Ltd Recent Development Table 117. Apotex Corporation Information Table 118. Apotex Description and Business Overview Table 119. Apotex Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 120. Apotex Product Table 121. Apotex Recent Development Table 122. BIOCAD Corporation Information Table 123. BIOCAD Description and Business Overview Table 124. BIOCAD Oncology Biosimilars Sales (K g), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 125. BIOCAD Product Table 126. BIOCAD Recent Development Table 127. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 128. Key Challenges Table 129. Market Risks Table 130. Main Points Interviewed from Key Oncology Biosimilars Players Table 131. Oncology Biosimilars Customers List Table 132. Oncology Biosimilars Distributors List Table 133. Research Programs/Design for This Report Table 134. Key Data Information from Secondary Sources Table 135. Key Data Information from Primary Sources List of Figures Figure 1. Oncology Biosimilars Product Picture Figure 2. Global Oncology Biosimilars Sales Market Share by Type in 2020 & 2026 Figure 3. mAb Product Picture Figure 4. Immunomodulators Product Picture Figure 5. Hematopoietic Agents Product Picture Figure 6. G-CSF Product Picture Figure 7. Others Product Picture Figure 8. Global Oncology Biosimilars Sales Market Share by Application in 2020 & 2026 Figure 9. Retail Pharmacies Figure 10. Hospital Pharmacy Figure 11. Online Pharmacy Figure 12. Oncology Biosimilars Report Years Considered Figure 13. Global Oncology Biosimilars Market Size 2015-2026 (US$ Million) Figure 14. Global Oncology Biosimilars Sales 2015-2026 (K g) Figure 15. Global Oncology Biosimilars Market Size Market Share by Region: 2020 Versus 2026 Figure 16. Global Oncology Biosimilars Sales Market Share by Region (2015-2020) Figure 17. Global Oncology Biosimilars Sales Market Share by Region in 2019 Figure 18. Global Oncology Biosimilars Revenue Market Share by Region (2015-2020) Figure 19. Global Oncology Biosimilars Revenue Market Share by Region in 2019 Figure 20. Global Oncology Biosimilars Sales Share by Manufacturer in 2019 Figure 21. The Top 10 and 5 Players Market Share by Oncology Biosimilars Revenue in 2019 Figure 22. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 23. Global Oncology Biosimilars Sales Market Share by Type (2015-2020) Figure 24. Global Oncology Biosimilars Sales Market Share by Type in 2019 Figure 25. Global Oncology Biosimilars Revenue Market Share by Type (2015-2020) Figure 26. Global Oncology Biosimilars Revenue Market Share by Type in 2019 Figure 27. Global Oncology Biosimilars Market Share by Price Range (2015-2020) Figure 28. Global Oncology Biosimilars Sales Market Share by Application (2015-2020) Figure 29. Global Oncology Biosimilars Sales Market Share by Application in 2019 Figure 30. Global Oncology Biosimilars Revenue Market Share by Application (2015-2020) Figure 31. Global Oncology Biosimilars Revenue Market Share by Application in 2019 Figure 32. Japan Oncology Biosimilars Sales Growth Rate 2015-2026 (K g) Figure 33. Japan Oncology Biosimilars Revenue Growth Rate 2015-2026 (US$ Million) Figure 34. Japan Oncology Biosimilars Market Share in Global Market 2015-2026 Figure 35. Japan 5 and 10 Largest Oncology Biosimilars Players Market Share by Revenue in Oncology Biosimilars in 2019 Figure 36. Japan Oncology Biosimilars Revenue Share by Type (2015-2020) Figure 37. Japan Oncology Biosimilars Revenue Growth Rate by Type in 2015 & 2019 Figure 38. Japan Oncology Biosimilars Revenue Share by Application (2015-2020) Figure 39. Japan Oncology Biosimilars Revenue Growth Rate by Application in 2015 & 2019 Figure 40. North America Oncology Biosimilars Sales Growth Rate 2015-2020 (K g) Figure 41. North America Oncology Biosimilars Revenue Growth Rate 2015-2020 (US$ Million) Figure 42. North America Oncology Biosimilars Sales Market Share by Country in 2019 Figure 43. North America Oncology Biosimilars Revenue Market Share by Country in 2019 Figure 44. U.S. Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 45. U.S. Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. Canada Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 47. Canada Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. Europe Oncology Biosimilars Sales Growth Rate 2015-2020 (K g) Figure 49. Europe Oncology Biosimilars Revenue Growth Rate 2015-2020 (US$ Million) Figure 50. Europe Oncology Biosimilars Sales Market Share by Country in 2019 Figure 51. Europe Oncology Biosimilars Revenue Market Share by Country in 2019 Figure 52. Germany Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 53. Germany Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. France Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 55. France Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. U.K. Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 57. U.K. Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Italy Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 59. Italy Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Russia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 61. Russia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Asia Pacific Oncology Biosimilars Sales Growth Rate 2015-2020 (K g) Figure 63. Asia Pacific Oncology Biosimilars Revenue Growth Rate 2015-2020 (US$ Million) Figure 64. Asia Pacific Oncology Biosimilars Sales Market Share by Region in 2019 Figure 65. Asia Pacific Oncology Biosimilars Revenue Market Share by Region in 2019 Figure 66. China Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 67. China Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Japan Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 69. Japan Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. South Korea Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 71. South Korea Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. India Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 73. India Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. Australia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 75. Australia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Taiwan Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 77. Taiwan Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Indonesia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 79. Indonesia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Thailand Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 81. Thailand Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 82. Malaysia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 83. Malaysia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 84. Philippines Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 85. Philippines Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 86. Vietnam Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 87. Vietnam Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 88. Latin America Oncology Biosimilars Sales Growth Rate 2015-2020 (K g) Figure 89. Latin America Oncology Biosimilars Revenue Growth Rate 2015-2020 (US$ Million) Figure 90. Latin America Oncology Biosimilars Sales Market Share by Country in 2019 Figure 91. Latin America Oncology Biosimilars Revenue Market Share by Country in 2019 Figure 92. Mexico Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 93. Mexico Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 94. Brazil Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 95. Brazil Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 96. Argentina Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 97. Argentina Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 98. Middle East and Africa Oncology Biosimilars Sales Growth Rate 2015-2020 (K g) Figure 99. Middle East and Africa Oncology Biosimilars Revenue Growth Rate 2015-2020 (US$ Million) Figure 100. Middle East and Africa Oncology Biosimilars Sales Market Share by Country in 2019 Figure 101. Middle East and Africa Oncology Biosimilars Revenue Market Share by Country in 2019 Figure 102. Turkey Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 103. Turkey Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 104. Saudi Arabia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 105. Saudi Arabia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 106. U.A.E Oncology Biosimilars Sales Growth Rate (2015-2020) (K g) Figure 107. U.A.E Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million) Figure 108. Porter's Five Forces Analysis Figure 109. Oncology Biosimilars Value Chain Figure 110. Channels of Distribution Figure 111. Distributors Profiles Figure 112. Bottom-up and Top-down Approaches for This Report Figure 113. Data Triangulation Figure 114. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us